Colorectal cancer is an important public health problem. Several screening methods have been shown to be effective in reducing colorectal cancer mortality. The objective of this review was to assess the cost-effectiveness of the different colorectal cancer screening methods and to determine the preferred method from a cost-effectiveness point of view. Five databases (MEDLINE, EMBASE, the Cost-Effectiveness Analysis Registry, the British National Health Service Economic Evaluation Database, and the lists of technology assessments of the Centers for Medicare and Medicaid Services) were searched for cost-effectiveness analyses published in English between January 1993 and December 2009. Fifty-five publications relating to 32 unique cost-effectiveness models were identified. All studies found that colorectal cancer screening was cost-effective or even cost-saving compared with no screening. However, the studies disagreed as to which screening method was most effective or had the best incremental cost-effectiveness ratio for a given willingness to pay per life-year gained. There was agreement among studies that the newly developed screening tests of stool DNA testing, computed tomographic colonography, and capsule endoscopy were not yet cost-effective compared with the established screening options.

中文翻译：

---

结直肠癌筛查的成本效益。

结直肠癌是一个重要的公共卫生问题。几种筛查方法已被证明可有效降低结直肠癌死亡率。本次审查的目的是评估不同结直肠癌筛查方法的成本效益，并从成本效益的角度确定首选方法。搜索了五个数据库（MEDLINE、EMBASE、成本效益分析登记处、英国国家卫生服务经济评估数据库以及医疗保险和医疗补助服务中心的技术评估列表），以查找 1 月期间以英文发布的成本效益分析1993 年和 2009 年 12 月。确定了与 32 个独特的成本效益模型相关的 55 份出版物。所有研究都发现，与不进行筛查相比，结直肠癌筛查具有成本效益甚至节省成本。然而，这些研究不同意哪种筛查方法最有效，或者对于给定的每增加生命年的支付意愿具有最佳的增量成本效益比。研究之间一致认为，与既定的筛查选项相比，新开发的粪便 DNA 检测、计算机断层扫描结肠成像和胶囊内镜检查等筛查测试尚不具有成本效益。